A practical reference on Reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
In the aftermath of World War II, the USAAF consolidated much of its wartime combat force and selected the P-51 as a "standard" piston-engined fighter, while other types, such as the P-38 and P-47, were withdrawn or given substantially reduced roles. As the more advanced (P-80 and P-84) jet fighters were introduced, the P-51 was also relegated to secondary duties. In 1947, the newly formed USAF Strategic Air Command employed fighter Mustangs alongside F-6 Mustangs and F-82 Twin Mustangs, due to their range capabilities. In 1948 a new designation scheme for USAF aircraft was introduced, with the prefix "P-" for "pursuit" changed to "F-" for "fighter" and the existing "F-" designation for photographic reconnaissance replaced with "RF-;" Mustang variants still in service in the USAF or Air National Guard (ANG) when the system was changed included: F-51B, F-51D, F-51K, RF-51D (formerly F-6D), RF-51K (formerly F-6K) and TRF-51D (two-seat trainer conversions of F-6Ds). By 1950, the majority of the USAF's Mustangs had become surplus to requirements and had been placed in storage or transferred to the Air Force Reserve and the ANG.
== Academic background == Gerngross received a M.S. (Dipl. Ing.) in chemical engineering (1989) and later a Ph.D. in molecular biology from the Technical University of Vienna, Austria. Following his studies in Austria he became a visiting scientist at the Massachusetts Institute of Technology in the laboratory of the late Arnold Demain (1989–91) and later joined the laboratory of Anthony Sinskey and JoAnne Stubbe at MIT as a postdoctoral associate from 1991 to 1993. From 1993 till 1998 he headed the fermentation and process development group at Metabolix Inc., a small startup company in Cambridge, Massachusetts. In 1998 he left industry to join the faculty at Dartmouth where he focused his research on protein engineering, glycoprotein engineering in yeast, and life cycle analysis of competing manufacturing technologies. In addition to this work, Gerngross’ lab also developed a novel protein expression system based on the industrial fermentation organisms Ralstonia eutropha, formerly Alcaligenes eutrophus. With certain model proteins, this expression system has shown to outperform E. coli, the well proven workhorse of prokaryotic protein expression. The work on Ralstonia eutropha was later expanded in collaboration with Prof. Wood at Princeton University to combine recombinant expression of proteins with the ability to purify them in vivo. In the late 1990s Gerngross became one of the first vocal critics of biobased processes.
== Biochemistry == Psilocin was first reported in this species in Benedict et al., 1962, and a few years later, Leung and Paul would report the related compound baeocystin, isolated from saprophytic culture, as well as the desmethyl metabolite norbaeocystin. Beug and Bigwood (1981) also reported on the concentrations of these compounds in Psilocybe baeocystis using reverse-phase HPLC and thin-layer chromatography. Concentration ranges for psychoactive compounds from these studies were reported to be 0.15–0.85% psilocybin, up to 0.59% psilocin, and up to 0.10% baeocystin.
Sources: en.wikipedia.org
=== Type 2 diabetes === There are contradictory reviews. From one, vitamin C supplementation cannot be recommended for management of type 2 diabetes. However, another reported that supplementation with high doses of vitamin C can decrease blood glucose, insulin and hemoglobin A1c.
== Treatment == The goal of glaucoma management for patients with increased intraocular pressure is to decrease the intraocular pressure (IOP), thus slowing the progression of glaucoma and preserving the quality of life for patients, with minimal side-effects. This requires appropriate diagnostic techniques and follow-up examinations, and judicious selection of treatments for the individual patient. Although increased IOP is only one of the major risk factors for glaucoma, lowering it via various pharmaceuticals and/or surgical techniques is currently the mainstay of glaucoma treatment. Vascular flow and neurodegenerative theories of glaucomatous optic neuropathy have prompted studies on various neuroprotective therapeutic strategies, including nutritional compounds, some of which may be regarded by clinicians as safe for use now, while others are on trial. Mental stress is also considered as consequence and cause of vision loss which means that stress management training, autogenic training and other techniques to cope with stress can be helpful.
==== Type III ==== Collagen quantity is sufficient, but is not of a high enough quality. Clinical differentiation between types III and IV is not always simple, and is further confounded by the fact that an untreated adult with type IV may have worse symptoms than a treated adult with type III; features only found in type III are its progressively deforming nature and the presence of a face with a "triangular" appearance. Another differentiating factor between type III and IV is blue sclerae; in type III, infants commonly have blue sclerae that gradually turn white with age, but blue sclerae are not commonly seen in type IV, although they are seen in 10% of cases. OI type III causes osteopenic bones that fracture very easily, sometimes even in utero, often leading to hundreds of fractures during a lifetime; early scoliosis that progresses until puberty; dwarfism (a final adult height frequently less than 4 feet or 120 centimetres); loose joints; and possible respiratory problems due to low rib cage volume causing low lung volumes. Due to the severity of the issues with the bones, neurological and seizure disorders are more likely to develop in type III. Basilar invagination, which puts pressure on the brainstem, may cause or contribute to early death; surgical treatment of it is more complex in OI cases.
== Adverse effects == Among those with keratoconus who worsen, CXL may be used. In this group, the most common side effects are haziness of the cornea, punctate keratitis, corneal striae, corneal epithelium defect, and eye pain. In those who use it after post-LASIK ectasia, the most common side effects are haziness of the cornea, corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, and sensitivity to bright lights. There are no long-term studies about crosslinking effect on pregnancy and lactation. According to a manufacturer crosslinking should not be performed on pregnant women.
Sources: en.wikipedia.org
=== Biological === Thorium is odourless and tasteless. The chemical toxicity of thorium is low because thorium and its most common compounds (mostly the dioxide) are poorly soluble in water, precipitating out before entering the body as the hydroxide. Some thorium compounds are chemically moderately toxic, especially in the presence of strong complex-forming ions such as citrate that carry the thorium into the body in soluble form. If a thorium-containing object has been chewed or sucked, it loses 0.4% of thorium and 90% of its dangerous daughters to the body. Three-quarters of the thorium that has penetrated the body accumulates in the skeleton. Absorption through the skin is possible, but is not a likely means of exposure. Thorium's low solubility in water also means that excretion of thorium by the kidneys and faeces is rather slow. Tests on the thorium uptake of workers involved in monazite processing showed thorium levels above recommended limits in their bodies, but no adverse effects on health were found at those moderately low concentrations. No chemical toxicity has yet been observed in the tracheobronchial tract and the lungs from exposure to thorium. People who work with thorium compounds are at a risk of dermatitis. It can take as much as thirty years after the ingestion of thorium for symptoms to manifest themselves. Thorium has no known biological role. However, a study by Tonietti et al. showed that some microorganisms can mobilize thorium through bioleaching processes.
Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise. It contains insulin degludec and liraglutide. It is administered by subcutaneous injection. The most common side effects include hypoglycaemia (low blood glucose). Side effects on the digestive system include nausea (feeling sick), diarrhea, vomiting, constipation, dyspepsia (indigestion), gastritis (inflammation of the stomach), abdominal pain (stomach ache), flatulence (wind), gastroesophageal reflux disease (passage of stomach acid back up towards the mouth), and distension (swelling) of the belly. Insulin degludec is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced. Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time. Liraglutide belongs to the class of diabetes medicines known as GLP-1 receptor agonists It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.
Former Yemeni president Ali Abdullah Saleh had accused the Houthis of having ties to external backers, in particular the Iranian government; Saleh stated in an interview with The New York Times,The real reason they received unofficial support from Iran was because they repeat same slogan that is raised by Iran – death to America, death to Israel. We have another source for such accusations. The Iranian media repeats statements of support for these [Houthi] elements. They are all trying to take revenge against the USA on Yemeni territories. Such backing has been reported by diplomatic correspondents of major news outlets (e.g., Patrick Wintour of The Guardian), and has been the reported perspective of Yemeni governmental leaders militarily and politically opposing Houthi efforts (e.g., as of 2017, the UN-recognized, deposed Yemeni President Abd Rabbu Mansour Hadi, who referred to the "Houthi rebels... as 'Iranian militias'". The Houthis in turn accused the Saleh government of being backed by Saudi Arabia and of using Al-Qaeda to repress them. Under the next President Hadi, Gulf Arab states accused Iran of backing the Houthis financially and militarily, though Iran denied this, and they were themselves backers of President Hadi. Despite confirming statements by Iranian and Yemeni officials in regards to Iranian support in the form of trainers, weaponry, and money, the Houthis denied reception of substantial financial or arm support from Iran.
The International Conference of Harmonisation Guidelines for Good Clinical Practice is a set of standards used internationally for the conduct of clinical trials. The guidelines aim to ensure the "rights, safety and well being of trial subjects are protected". The notion of informed consent of participating human subjects exists in many countries but its precise definition may still vary. Informed consent is clearly a 'necessary' condition for ethical conduct but does not 'ensure' ethical conduct. In compassionate use trials the latter becomes a particularly difficult problem. The final objective is to serve the community of patients or future patients in a best-possible and most responsible way. See also Expanded access. However, it may be hard to turn this objective into a well-defined, quantified, objective function. In some cases this can be done, however, for instance, for questions of when to stop sequential treatments (see Odds algorithm), and then quantified methods may play an important role. Additional ethical concerns are present when conducting clinical trials on children (pediatrics), and in emergency or epidemic situations. Ethically balancing the rights of multiple stakeholders may be difficult. For example, when drug trials fail, the sponsors may have a duty to tell current and potential investors immediately, which means both the research staff and the enrolled participants may first hear about the end of a trial through public business news.
=== RNaseA === In 1959, Fred Richards discovered that a proteolytic enzyme, Subtilisin, had the ability to cleave the enzyme Ribonuclease A into two components, a peptide corresponding to the first 20 amino acids of the enzyme (S-Peptide) and the remainder of the protein (S-Protein). When separated from one another, each piece was inactive but when they were simply mixed together, full enzymatic activity was restored. Hofmann speculated that this system might be a model for the way peptide hormones interact with their receptors. Structure-function studies with ACTH were complicated by the necessity to assess activity in the whole animal. The S-Peptide:S-Protein system afforded a simple system with none of the biological complications inherent in testing ACTH analogs. To study which amino acids might be important in establishing the binding between peptide hormones and their receptors, Hofmann and his group began a systematic evaluation of the contributions each amino acid in the S-Peptide molecule made to the binding with S-Protein. The ability of synthetic analogs of S-Peptide to activate S-Protein correlated well with those of synthetic ACTH analogs to elicit hormonal activity: 1) only a portion of the S-Peptide chain was essential for re-establishing full activity with the S-Protein; 2) methionine was not important; 3) substituting one particular amino acid in the peptide not only destroyed the activity of the peptide but created an antagonist as well.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.